Global Generics adjusted gross margin decreased 3.4 percentage points to 45.2 percent in the second quarter 2011. Adjusted Global Generics gross margin was negatively impacted by the launch of methylphenidate ER.
Global Generics R&D investment for second quarter 2011 increased 31 percent to $58.3 million, primarily due to increased clinical study costs and increased investment in international R&D. Six new products were launched in the U.S. and we had seven new patent challenges during the quarter.
Global Brands Segment InformationThree Months EndedJune 30,Six Months EndedJune 30,(Unaudited; $ in millions)
112.9103.5209.8194.8Operating expenses:Cost of sales
25.123.642.948.3Research and development
188.8.131.52.5Selling and marketing
77.8%77.2%79.6%75.2%Global Brands net revenue increased nine percent to $112.9 million in the second quarter 2011 as a result of the addition of new products including Crinone®, Generess™ Fe and Nulecit™ and increased sales of RAPAF
|SOURCE Watson Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved